Session

Bladder pain syndrome: Evolving strategies

Poster Session 34

  • Location:
    Room 14a (ICM, Level 1)
  • Chairs:
     P. Dinis Oliveira, Porto (PT)
     D.S. Engeler, St. Gallen (CH)
     H-C. Kuo, Hualien (TW)
  • Aims and objectives of this session

    New and old treatment options

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (*) are 3 minutes in length, followed by 3 minutes for discussion.
* 418
Immunotherapy to treat bladder painful syndrome

By: Augé C.2, Lluel P.2, Vergnolle N.1, Dietrich G.1

Institutes: 1Purpan Hospital, Inserm Umr1043, Toulouse, France, 2UROsphere, Dept. of Pharmacology, Toulouse, France

419
Toll like receptor 7 is overexpressed in the bladder mucosa of Hunner type interstitial cystitis and its activation in the mouse bladder induces cystitis and pain

By: Ichihara K.1, Aizawa N.1, Sugiyama R.1, Ito H.1, Kamei J.1, Akiyama Y.1, Masumori N.2, Andersson K-E.4, Homma Y.3, Igawa Y.1

Institutes: 1The University of Tokyo Graduate School of Medicine, Dept. of Continence Medicine, Tokyo, Japan, 2Sapporo Medical University School of Medicine, Dept. of Urology, Sapporo, Japan, 3The University of Tokyo Graduate School of Medicine, Dept. of Urology, Tokyo, Japan, 4Aarhus University, Aarhus Institute of Advanced Studies, Aarhus, Denmark

420
Development and validation of a clinically-relevant chronic model of interstitial cystitis/bladder painful syndrome

By: Chabot S.1, Augé C.1, Meen M.1, Guilloteau V.1, Vergnolle N.2, Gamé X.3, Lluel P.1

Institutes: 1Urosphere, Dept. of Urology, Toulouse, France, 2INSERM UMR1043, Purpan University Hospital, Toulouse, France, 3INSERM I2MC-U1048, Rangueil University Hospital, Dept. of Urology, Toulouse, France

* 421
Comparison of Cystistat®, iAluril®, and Whitmore Cocktail for treatment of patients with bladder pain syndrome/interstitial cystitis

By: Cocci A.1, Alowidah I.2, Skews R.2, Hashim H.2

Institutes: 1University of Florence, Dept. of Urology, Florence, Italy, 2Bristol Urological Institute, Dept. of Urology, Bristol, United Kingdom

422
Pelvic inflammatory disease is associated with bladder pain syndrome/interstitial cystitis: A population-based case-control study

By: Tan J-S.

Institutes: Far Eastern Memorial Hospital, Dept. of Urology, New Taipei City, Taiwan

423
The effect of intravesical liposome-based NGF antisense therapy on bladder overactivity and nociception in a rat model of cystitis induced by hydrogen peroxide

By: Majima T.1, Tyagi P2, Dogishi K.3, Kashyap M.2, Gotoh M.1, Chancellor M.B.4, Yoshimura N.2

Institutes: 1Nagoya University School of Medicine, Dept. of Urology, Nagoya, Japan, 2University of Pittsburgh, Dept. of Urology, Pittsburgh, United States of America, 3University of Kyoto, Dept. of Molecular Pharmacology, Kyoto, Japan, 4Oakland University William Beaumont School of Medicine, Dept. of Urology, Royal Oak, United States of America

424
Chronic pelvic pain syndrome is similar as features and symptoms of occlusive lesions of common and internal iliac arteries

By: Belousov I., Kogan M.I.

Institutes: Rostov State Medical University, Dept. of Urology, Rostov on Don, Russia

425
Analysis of multiple urine markers for the detection of interstitial cystitis/bladder pain syndrome in patients with lower urinary tract symptoms

By: Furuta A.1, Yamamoto T.2, Koike Y.1, Suzuki Y.3, Gotoh M.2, Egawa S.4, Yoshimura N.5

Institutes: 1Jikei University School Of Medicine, Dept. of Urology, Tokyo, Japan, 2Nagoya University Graduate School of Medicine, Dept. of Urology, Nagoya, Japan, 3Tokyo Metropolitan Rehabilitation Hospital, Dept. of Urology, Tokyo, Japan, 4Jikei University School of Medicine, Dept. of Urology, Tokyo, Japan, 5University of Pittsburgh School of Medicine, Dept. of Urology, Pennsylvania, United States of America

426
Possible role of matrix metalloproteinase-8 in pathophysiology of interstitial cystitis/painful bladder syndrome

By: Piecha T.1, Poletajew S.1, Wyczałkowska-Tomasik A.2, Gala K.2, Burdzińska A.2, Pączek L.2, Radziszewski P.1

Institutes: 1Medical University of Warsaw, Dept. of General, Oncological and Functional Urology, Warsaw, Poland, 2Medical University of Warsaw, Dept. of Immunology, Transplantation and Internal Diseases, Warsaw, Poland

427
Plasma and urinary pharmacokinetics of the novel, oral SHIP1 activator, AQX-1125 in interstitial cystitis/bladder pain syndrome (IC/BPS): Results of the phase2 LEADERSHIP trial

By: Nickel C.2, Evans R.3, Tam P.4, Toews J.4, MacKenzie L.4, Biagi H.1, Shrewsbury S.1

Institutes: 1Aquinox Pharmaceuticals, Dept. of Clinical Development, Vancouver, Canada, 2Queen’s University, Dept. of Urology, Kingston, Canada, 3Wake Forest University Health Sciences, Dept. of Urology, Winston Salem, United States of America, 4Aquinox Pharmaceuticals, Dept. of Technical Operations, Vancouver, Canada

429
5-HT in the rat prefrontal cortex controls the micturition reflex via 5-HT2A and 5-HT7

By: Hiroki C.1, Mitsui T.2, Kitta T.1, Ohmura Y.3, Moriya K.1, Kanno Y.1, Yoshioka M.3, Shinohara N.1

Institutes: 1Hokkaido University, Dept. of Urology, Sapporo, Japan, 2Yamanashi University, Dept. of Urology, Yamanashi, Japan, 3Hokkaido University, Dept. of Neuropharmacology, Sapporo, Japan

Summary and context
 P. Dinis Oliveira, Porto (PT)